Cure8 news brief
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a regulatory update related to Risankizumab, IL-23 inhibitor, and Medications. Use the original source link for the full details.
The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.
Review the original publication for the complete reporting, methods, and context.
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
A subcutaneous induction option for SKYRIZI could let people with Crohn’s start and continue treatment with injections instead of beginning with an IV infusion, which may affect convenience, time in clinic, and infusion...
A new subcutaneous induction option for risankizumab could make starting this biologic easier for many adults with moderate-to-severe Crohn's disease by avoiding infusions, potentially increasing access and convenience.
A new subcutaneous induction option for risankizumab could make starting IL‑23 therapy more convenient for adults with moderately to severely active Crohn’s disease and expand choices for those who have failed prior...
